HRP20160832T1 - Liječenje osteoporoze - Google Patents
Liječenje osteoporoze Download PDFInfo
- Publication number
- HRP20160832T1 HRP20160832T1 HRP20160832TT HRP20160832T HRP20160832T1 HR P20160832 T1 HRP20160832 T1 HR P20160832T1 HR P20160832T T HRP20160832T T HR P20160832TT HR P20160832 T HRP20160832 T HR P20160832T HR P20160832 T1 HRP20160832 T1 HR P20160832T1
- Authority
- HR
- Croatia
- Prior art keywords
- substance
- formula
- carbon atoms
- osteoporosis
- osteopenia
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims 12
- 239000000126 substance Substances 0.000 claims 16
- 125000004432 carbon atom Chemical group C* 0.000 claims 13
- 208000029725 Metabolic bone disease Diseases 0.000 claims 10
- 206010049088 Osteopenia Diseases 0.000 claims 10
- 125000004122 cyclic group Chemical group 0.000 claims 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 229910003827 NRaRb Inorganic materials 0.000 claims 3
- 241000036848 Porzana carolina Species 0.000 claims 3
- 230000037182 bone density Effects 0.000 claims 3
- 239000000701 coagulant Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- BCNIZSHMXASUGF-YRNVUSSQSA-N 2-methyl-3-[(2E)-5-carboxy-3-methylpent-2-enyl]-1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C(C\C=C(CCC(O)=O)/C)=C(C)C(=O)C2=C1 BCNIZSHMXASUGF-YRNVUSSQSA-N 0.000 claims 2
- 206010065687 Bone loss Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- HRXALBJWEAUTGI-VQHVLOKHSA-N (e)-2-methyl-4-(3-methyl-1,4-dioxonaphthalen-2-yl)but-2-enoic acid Chemical compound C1=CC=C2C(=O)C(C\C=C(/C)C(O)=O)=C(C)C(=O)C2=C1 HRXALBJWEAUTGI-VQHVLOKHSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229930003448 Vitamin K Natural products 0.000 claims 1
- 230000008468 bone growth Effects 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 235000019168 vitamin K Nutrition 0.000 claims 1
- 239000011712 vitamin K Substances 0.000 claims 1
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 1
- 229940046010 vitamin k Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Claims (13)
1. Tvar formule (I)
[image]
gdje
R1 predstavlja vodik, halogen, cijano, trifluorometil, nitro, -ORa, SRa, SORa, -SO2Ra, -SO2NRaRb, -NRaRb, -NRaCORb, -NRaCO2Rb, -CORa, -CO2Ra, -CONRaRb, ili ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, ili heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom;
R2 predstavlja, nezavisno pri svakom pojavljivanju, vodik, halogen, cijano, trifluorometil, nitro, -ORa, SRa, SORa, -SO2Ra, -SO2NRaRb, -NRaRb, -NRaCORb, -NRaCO2Rb, -CORa, -CO2Ra, -CONRaRb, ili ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, ili heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom;
R3 predstavlja ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, supstituiranu s barem jednom jedinicom koja uključuje supstituend -CO2Ra, pri čemu je R3 predstavljen sljedećom formulom (II);
[image]
gdje slobodna veza predstavlja točku vezanja strukturnog dijela Formule (II) na ostatak tvari Formule (I);
Rc, Rd i Re su nezavisno odabrani između vodika ili C1-6 alikla (koji može biti ravnolančani ili razgranati);
q je 1, 2, 3 ili 4;
r i s su nezavisno odabrani između 0, 1, 2, 3 ili 4;
[image]
predstavlja dvostruku vezu, a Re nije prisutan izvan formule (II);
opcionalno gdje je strukturni fragment Formule (II) odabran između:
[image]
gdje Ra i Rb nezavisno predstavljaju, pri svakom pojavljivanju, vodik, ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, ili heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom; i
n je 0, 1, 2, 3 ili 4;
ili farmaceutski prihvatljiv solvat ili, pobliže, njenu sol; za uporabu u liječenju osteoporoze i/ili osteopenije.
2. Tvar za uporabu u skladu s patentnim zahtjevom 1, pri čemu:
R1 ili R2 predstavlja vodik, halogen, cijano, trifluorometil, nitro, -ORa, SRa, SORa, -SO2Ra, -SO2NRaRb, -NRaRb, -NRaCORb, -NRaCO2Rb, -CORa, -CO2Ra, -CONRaRb, ili ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, ili heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom;
gdje Ra i Rb nezavisno predstavljaju vodik, ili ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, ili heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom;
n je 1, 2, 3 ili 4;
opcionalno gdje R1 predstavlja alkilnu grupu uključujući ravnolančane ili razgranate alikilne grupe koje sadrže 1 do 9 atoma ugljika.
3. Tvar za uporabu u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, pri čemu:
R1 predstavlja ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, opcionalno gdje R1 predstavlja metil.
4. Tvar za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 i 3 pri čemu n predstavlja 0.
5. Tvar za uporabu u skladu s bilo kojim od patentnih zahtjeva 2 ili 3 pri čemu n predstavlja 4 i R2, pri svakom pojavljivanju, predstavlja vodik.
6. Tvar za uporabu u skladu s bilo kojim prethodnim patentnim zahtjevom, gdje je tvar formule (I) odabrana iz liste koja sadrži:
(i) NaKvinat-Me (VII); pobliže,
(ii) (4E)-6-(1,4-dihidro-2-metil-1,4-dioksonaftalen-3-il)-4-metilheks-4-enoičnu kiselinu (VIII);
(iii) (2E)-4-(1,4-dihidro-2-metil-1,4-dioksonaftalen-3-il)-2-metilbut-2-enoičnu kiselinu (XIV).
7. Farmaceutski sastav obuhvaća tvar formule (I) kako je definirano u bilo kojem od patentnih zahtjeva 1 do 6 i njen farmaceutski prihvatljivi nosač, diluent ili ekscipijens, za uporabu u liječenju osteoporoze i/ili osteopenije.
8. Tvar formule (I) kako je definirano u bilo kojem od patentnih zahtjeva 1 do 6, ili sastav u skladu s patentnim zahtjevom 7, za uporabu u prevenciji gubitka kostiju, umanjivanja gubitka kostiju, stimulaciji rasta kostiju, stvaranju povećane gustoće kostiju kod potrebitog pacijanta i/ili liječenju ili prevenciji osteoporoze mirovanja, ili za uporabu u prevenciji ili liječenju osteoporoze i/ili osteopenije kod pacijanta na način:
(a) sprječavanjem smanjenja gustoće kostiju u pacijanta podložnog osteoporozi i/ili osteopeniji; ili
(b) sprječavanjem ili umanjivanjem pada u gustoći kostiju kod pacijenta koji pati od osteoporoze i/ili osteopenije.
9. Tvar formule (I) kako je definirana u bilo kojem od patentnih zahtjeva 1 do 6, ili farmaceutski sastav kako je definiran u patentnom zahtjevu 7, za uporabu kao dio kombinirane terapije zajedno s drugim terapijskim agensom za uporabu u liječenju osteoporoze i/ili osteopenije.
10. Kombinacija produkta obuhvaća:
(A) tvar formule (I), kako je definirana u bilo kojem od patentnih zahtjeva 1 do 6, i
(B) drugi terapijski agens,
gdje je svaka od komponenata (A) i (B) formulirana u smjesi s farmaceutski prihvatljivim adjuvansom, diluentom ili nosačem, za uporabu u liječenju osteoporoze i/ili osteopenije.
11. Farmaceutska formulacija koja uključuje tvar formule (I), kako je definirana u bilo kojem od patentnih zahtjeva 1 do 6 i drugi terapijski agens, u smjesi s farmaceutski prihvatljivim adjuvansom, diluentom ili nosačem, za uporabu u liječenju osteoporoze i/ili osteopenije.
12. Komplet dijelova obuhvaća bilo:
komponente:
(i) farmaceutsku formulaciju koja uključuje tvar formule (I), kako je definirana u bilo kojem od patentnih zahtjeva 1 do 6, u smjesi s farmaceutski prihvatljivim adjuvansom, diluentom ili nosačem; i
(ii) farmaceutsku formulaciju koja uključuje drugi terapijski agens, u smjesi s farmaceutski prihvatljivim adjuvansom, diluentom ili nosačem,
gdje je svaka od komponenata (i) i (ii) omogućena u obliku pogodnom za primjenu zajedno s drugom;
ili obuhvaća
tvar iz bilo kojeg od patentnih zahtjeva 1 do 6 ili sastav iz patentnog zahtjeva 7 i koagulans;
uporabu u liječenju osteoporoze i/ili osteopenije.
13. Kombinacija tvari formule (I) kako je definirana u bilo kojem od patentnih zahtjeva 1 do 6 ili sastava iz patentnog zahtjeva 7 s koagulansom, gdje je opcionalno koagulans vitamin K, za uporabu u liječenju osteoporoze i/ili osteopenije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0922513.7A GB2476644B (en) | 2009-12-23 | 2009-12-23 | 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis |
| PCT/GB2010/052195 WO2011077159A1 (en) | 2009-12-23 | 2010-12-22 | Treatment of osteoporosis |
| EP10801459.8A EP2536398B1 (en) | 2009-12-23 | 2010-12-22 | Treatment of osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160832T1 true HRP20160832T1 (hr) | 2016-09-23 |
Family
ID=41716867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160832TT HRP20160832T1 (hr) | 2009-12-23 | 2016-07-11 | Liječenje osteoporoze |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8895624B2 (hr) |
| EP (1) | EP2536398B1 (hr) |
| JP (1) | JP5922033B2 (hr) |
| KR (1) | KR101805940B1 (hr) |
| CN (1) | CN103002886B (hr) |
| AU (1) | AU2010334566B2 (hr) |
| BR (1) | BR112012017773B1 (hr) |
| CA (1) | CA2785553C (hr) |
| CY (1) | CY1117805T1 (hr) |
| DK (1) | DK2536398T3 (hr) |
| GB (1) | GB2476644B (hr) |
| HK (1) | HK1178057A1 (hr) |
| HR (1) | HRP20160832T1 (hr) |
| HU (1) | HUE028400T2 (hr) |
| IL (1) | IL220620A (hr) |
| PL (1) | PL2536398T3 (hr) |
| PT (1) | PT2536398T (hr) |
| RS (1) | RS54987B1 (hr) |
| RU (1) | RU2562976C2 (hr) |
| SI (1) | SI2536398T1 (hr) |
| SM (1) | SMT201600224B (hr) |
| WO (1) | WO2011077159A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2476644B (en) | 2009-12-23 | 2012-11-14 | Haomamedica Ltd | 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis |
| GB2476643B (en) * | 2009-12-23 | 2012-11-14 | Haomamedica Ltd | 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5640651A (en) * | 1979-09-12 | 1981-04-16 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
| JPS55153739A (en) | 1979-05-18 | 1980-11-29 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
| GB8310141D0 (en) * | 1983-04-14 | 1983-05-18 | Wellcome Found | Naphthoquinone derivatives |
| MX9203040A (es) | 1984-08-01 | 1992-07-31 | Takeda Chemical Industries Ltd | Derivados de quinona y composicion farmaceutica que los contiene. |
| WO1986000887A1 (en) | 1984-08-01 | 1986-02-13 | Takeda Chemical Industries, Ltd. | Quinone derivatives, process for their preparation, and medicinal composition containing the same |
| US4734282A (en) | 1986-04-23 | 1988-03-29 | Duke University | Rodenticidal compositions containing 1,4-naphthoquinone derivatives |
| JP2756941B2 (ja) | 1996-01-26 | 1998-05-25 | 東國製薬株式会社 | ２−クロロ−３−アリールアミノ−１，４−ナフトキノン誘導体の血小板凝集抑制剤としての用途 |
| GB9613309D0 (en) * | 1996-06-25 | 1996-08-28 | Univ Sheffield | Quinone bacterial inhibitors |
| US5849793A (en) * | 1997-08-15 | 1998-12-15 | The Picower Institute For Medical Research | HIV matrix protein tyrosine position 29 pocket binders |
| WO2001028547A1 (fr) * | 1999-10-19 | 2001-04-26 | Meiji Milk Products Co., Ltd | Produits alimentaires utiles dans la prevention et l'amelioration de maladies du metabolisme osseux et medicaments preventifs/therapeutiques pour des maladies du metabolisme osseux comprenant ces produits alimentaires |
| WO2003013420A2 (en) * | 2001-08-03 | 2003-02-20 | Vitak Bv | Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification |
| US20050222258A1 (en) | 2003-02-21 | 2005-10-06 | Feixin Wang | Pharmaceuticals comprising shikonins as active constituent |
| US20090137614A1 (en) * | 2005-05-27 | 2009-05-28 | Shionogi & Co., Ltd. | Pharmaceutical combination comprising vitamin k |
| PL2046312T3 (pl) * | 2006-07-14 | 2021-02-08 | Kaydence Pharma As | Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2 |
| GB2476644B (en) | 2009-12-23 | 2012-11-14 | Haomamedica Ltd | 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis |
| GB2476643B (en) | 2009-12-23 | 2012-11-14 | Haomamedica Ltd | 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants |
-
2009
- 2009-12-23 GB GB0922513.7A patent/GB2476644B/en active Active
-
2010
- 2010-12-22 PT PT108014598T patent/PT2536398T/pt unknown
- 2010-12-22 BR BR112012017773-7A patent/BR112012017773B1/pt not_active IP Right Cessation
- 2010-12-22 KR KR1020127019255A patent/KR101805940B1/ko active IP Right Grant
- 2010-12-22 RU RU2012130936/04A patent/RU2562976C2/ru active
- 2010-12-22 EP EP10801459.8A patent/EP2536398B1/en active Active
- 2010-12-22 JP JP2012545450A patent/JP5922033B2/ja active Active
- 2010-12-22 WO PCT/GB2010/052195 patent/WO2011077159A1/en active Application Filing
- 2010-12-22 DK DK10801459.8T patent/DK2536398T3/en active
- 2010-12-22 PL PL10801459.8T patent/PL2536398T3/pl unknown
- 2010-12-22 CA CA2785553A patent/CA2785553C/en active Active
- 2010-12-22 CN CN201080064615.0A patent/CN103002886B/zh active Active
- 2010-12-22 RS RS20160550A patent/RS54987B1/sr unknown
- 2010-12-22 HU HUE10801459A patent/HUE028400T2/en unknown
- 2010-12-22 SI SI201031228A patent/SI2536398T1/sl unknown
- 2010-12-22 AU AU2010334566A patent/AU2010334566B2/en active Active
- 2010-12-22 US US13/518,621 patent/US8895624B2/en active Active
-
2012
- 2012-06-24 IL IL220620A patent/IL220620A/en active IP Right Grant
-
2013
- 2013-04-26 HK HK13105097.6A patent/HK1178057A1/zh unknown
-
2014
- 2014-10-21 US US14/520,223 patent/US9622989B2/en active Active
-
2016
- 2016-07-11 HR HRP20160832TT patent/HRP20160832T1/hr unknown
- 2016-07-12 CY CY20161100668T patent/CY1117805T1/el unknown
- 2016-07-12 SM SM201600224T patent/SMT201600224B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101516840B (zh) | 取代的n-酰基苯胺及其应用方法 | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| JP2017537949A5 (hr) | ||
| JP2009510044A5 (hr) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20151000T1 (hr) | Antivirusni spojevi | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| JP2008509187A5 (hr) | ||
| RU2008109914A (ru) | Применение производных тиенопиридона в качестве активаторов амфк и фармацевтические композиции, которые их содержат | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| CA2777746A1 (en) | Benzoimidazole compounds and uses thereof | |
| PT1780197E (pt) | 5-substituinte-2-fenilamino benzamida como inibidor de mek | |
| CY1110014T1 (el) | Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm) | |
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| RU2015124002A (ru) | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| NO20064365L (no) | Terapeutisk forbindelse | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| JP2018537535A5 (hr) | ||
| JP2013507426A5 (hr) | ||
| JP2015522018A5 (hr) | ||
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| HRP20140326T1 (hr) | Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat |